Cynata Therapeutics (ASX:CYP) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Cynata Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cynata Therapeutics's Free Cash Flow for the six months ended in Dec. 2023 was A$-4.85 Mil. Cynata Therapeutics's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Therefore, Cynata Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Cynata Therapeutics's current FCF Yield % is -22.00%.

The historical rank and industry rank for Cynata Therapeutics's FCF Margin % or its related term are showing as below:

ASX:CYP's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -139.31
* Ranked among companies with meaningful FCF Margin % only.

Cynata Therapeutics FCF Margin % Historical Data

The historical data trend for Cynata Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cynata Therapeutics FCF Margin % Chart

Cynata Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Margin %

Get a 7-Day Free Trial

Cynata Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cynata Therapeutics's FCF Margin %

For the Biotechnology subindustry, Cynata Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cynata Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cynata Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Cynata Therapeutics's FCF Margin % falls into.

Cynata Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Cynata Therapeutics's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-14.283	/	0
	=	%

Cynata Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-4.853	/	0
	=	%

Cynata Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Cynata Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cynata Therapeutics (ASX:CYP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (ASX:CYP) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

51S:Germany

Address

100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121

Website

https://www.cynata.com

Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Cynata Therapeutics (ASX:CYP) Headlines

No Headlines